作者: Tameryn Stringer , Lubbe Wiesner , Gregory S. Smith
DOI: 10.1016/J.EJMECH.2019.06.023
关键词:
摘要: Abstract Rising resistance to conventional therapies for malaria has led the search novel drugs and strategies with distinct mechanisms of action that may overcome this. Ferroquine is currently gold standard as far antimalarial metal-based are concerned in phase IIb clinical trials part MMV pipeline (in partnership Sanofi) antimalarials. It assumed inhibit haemozoin formation like chloroquine maintain its activity resistant strain. Here we report two ferroquine-derived polyamines target a strain Plasmodium falciparum. Furthermore, upon treatment falciparum polyamine, cellular haem fractionation experiments reveal inhibition likely not mechanism responsible their activity, an important result aid further development.